AstraZeneca Rejig Brings Baselga On Board
Executive Summary
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.
You may also be interested in...
Shock As AstraZeneca’s Oncology R&D Head José Baselga Dies
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
Q4 Pharma Earnings Preview: GSK, Lilly, Sanofi And AstraZeneca
GlaxoSmithKline will update investors on strategy after completing its Tesaro acquisition. Lilly may have guidance updates following its Loxo acquisition and Lartruvo setback news. Sanofi investors await a pair of new approvals, and AstraZeneca faces investors for the first time since the departure of Chief Medical Officer Sean Bohen and establishing a new organizational structure.